Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767901 | 0.79 | TLR8 (0.37) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL19642681 | 0.78 | ALDH1A1 (0.37) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL692768 | 0.76 | KDR (0.36) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL693035 | 0.76 | ALDH1A1 (0.36) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL695822 | 0.75 | MPO (0.41) | CNR1CNR2TLR8MPO | |
| SCHEMBL1075036 | 0.75 | CYP1A2 (0.41) | MAPT | |
| SCHEMBL1030046 | 0.74 | KDR (0.34) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL693498 | 0.74 | ALDH1A1 (0.37) | CNR1CNR2TLR8KDRSLC9A1 | |
| SCHEMBL693027 | 0.74 | MPO (0.40) | TLR8KDRSLC9A1MPO | |
| SCHEMBL725352 | 0.74 | MPO (0.40) | TLR8KDRSLC9A1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274286-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | The Procter & Gamble Company (US) | 2011-01-19 | — | — | EP | claimed |
| US-7850742-B2 | Keratin dyeing compounds, keratin dyeing compositions containing said compounds, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2010-12-14 | — | — | US | claimed |
| WO-2009140451-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | NOXELL CORPORATION | 2009-11-19 | — | — | US | claimed |
| EP-2274286-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | The Procter & Gamble Company (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7850742-B2 | Keratin dyeing compounds, keratin dyeing compositions containing said compounds, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2010-12-14 | — | — | US | disclosed |
| WO-2009140451-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | NOXELL CORPORATION | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | KRT18, TUBB3, PPOX | CNR1 4671/4885CNR2 4620/4885TLR8 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.